Evofem Biosciences, Inc.
EVFM
$0.01
$0.00-5.26%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.51% | 3.70% | 6.28% | 26.09% | 19.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.51% | 3.70% | 6.28% | 26.09% | 19.54% |
| Cost of Revenue | -18.51% | -39.60% | -41.12% | -44.87% | -25.07% |
| Gross Profit | 2.62% | 28.43% | 32.66% | 81.44% | 47.68% |
| SG&A Expenses | 20.24% | 7.36% | -1.39% | -32.31% | -49.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.08% | -36.27% | -25.03% | -32.26% | -48.90% |
| Operating Income | 60.89% | 73.67% | 56.99% | 62.09% | 73.22% |
| Income Before Tax | -110.31% | -106.12% | -116.72% | -116.97% | -13.99% |
| Income Tax Expenses | -105.26% | -100.00% | -100.00% | -100.00% | -29.63% |
| Earnings from Continuing Operations | -110.31% | -106.13% | -116.72% | -116.97% | -13.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.31% | -106.13% | -116.72% | -116.97% | -13.98% |
| EBIT | 60.89% | 73.67% | 56.99% | 62.09% | 73.22% |
| EBITDA | 69.36% | 78.43% | 59.55% | 62.40% | 72.81% |
| EPS Basic | -100.40% | -100.27% | -102.41% | 86.71% | -87.02% |
| Normalized Basic EPS | 97.70% | 99.71% | 97.71% | 98.01% | -101.63% |
| EPS Diluted | 90.56% | 99.14% | 97.30% | 95.44% | 96.77% |
| Normalized Diluted EPS | 82.55% | 99.13% | 96.77% | 97.63% | -104.21% |
| Average Basic Shares Outstanding | 278.78% | 685.71% | 1,501.71% | 2,482.24% | 2,485.51% |
| Average Diluted Shares Outstanding | 166.40% | 914.43% | 148.11% | 138.92% | 29,052.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |